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Estrogen receptor-alpha (ERa)-positive breast cancer is often treated with
antihormonal regimens. However, resistance to treatment is common, lead-
ing to metastatic disease. ERa activity requires the functional involvement of
pioneer factors FOXA1 and GATA3, which enable ERa–chromatin binding
and are crucial for ERa-driven cell proliferation. FOXA1 was found
increased in metastatic breast cancers in relation to the primary tumor, but a
comprehensive clinical assessment thereof, in relation to different metastatic
sites and endocrine therapy usage, is currently lacking. Prior cell line-based
reports, however, have revealed that FOXA1 is required for tamoxifen-resis-
tant tumor cell proliferation. We studied expression levels of ERa, GATA3,
and FOXA1 by immunohistochemistry in samples from both primary tumors
and various metastatic sites. For all factors, expression levels varied between
the metastatic sites. For pleural metastases, strong variation was found in
FOXA1 and GATA3 levels. Although GATA3 levels remained unaltered
between primary breast cancer and pleural metastases, FOXA1 levels were
reduced exclusively in metastases of patients who received endocrine thera-
pies in the adjuvant setting, even though ERa was still expressed. Impor-
tantly, decreased FOXA1 levels in pleural metastases correlated with
hormone irresponsiveness in the palliative setting, while no such correlation
was found for GATA3. With this, we show divergent clinical correlations of
the two ERa pioneer factors FOXA1 and GATA3 in metastatic breast can-
cer, where endocrine therapy resistance was associated with decreased
FOXA1 levels in pleural metastases.
Abbreviations
CI, confidence interval; ERa, estrogen receptor-alpha; ESR1, estrogen receptor 1; FFPE, formalin-fixed paraffin-embedded; FOXA1, forkhead
box protein A1; GATA3, GATA binding protein 3; HR, hazard ratio; IHC, immunohistochemistry; TMA, tissue microarray.
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1. Introduction
Breast cancer is the most common malignancy in
women with 1.7 million newly diagnosed cases annu-
ally worldwide and over 550 000 patients succumbing
to the consequences of the disease each year (Ferlay
et al., 2015). Around 70% of all breast tumors are of
the luminal subtype, in which estrogen receptor-alpha
(ERa) is the main driver of cell proliferation, and con-
sequently the prime drug target in treatment (Beelen
et al., 2012; Droog et al., 2013). These patients are
generally treated with endocrine therapies in the adju-
vant setting: tamoxifen or aromatase inhibitors. Both
types of drugs prevent ERa-driven gene transcription,
subsequently blocking tumor cell proliferation and
tumor progression.
Despite an impressive reduction in recurrence risk,
relapses do occur after adjuvant endocrine therapy
(Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) et al., 2011). These relapses may be due to
either intrinsic or acquired drug resistance (Dalmau
et al., 2014). Several intrinsic resistance mechanisms to
hormonal intervention have been described, including
activation of kinase pathways (Kok et al., 2011; de
Leeuw et al., 2013; Zwart et al., 2007a) and overexpres-
sion of coregulators that are involved in ERa function
(Zwart et al., 2007b, 2009). All these resistance mecha-
nisms enable tumor cell proliferation despite hormonal
therapy, ultimately giving rise to outgrowth of meta-
static breast cancer (Kennecke et al., 2010).
Over the last years, acquired resistance to therapy
has gained scientific attention. As a proportion of
metastatic cancer cells of ERa-positive breast cancer
are likely to have evolved to proliferate and survive
under endocrine therapy, it may not seem surprising
that these resistance mechanisms can strongly differ
from those responsible for intrinsic treatment resis-
tance (Dalmau et al., 2014). Recently, several acquired
resistance mechanisms have been identified, including
activating mutations within the ESR1 gene (around
20% of cases) (Robinson et al., 2013; Toy et al.,
2013), genomewide reprogramming of the chromatin
landscape (Magnani et al., 2013), and loss of ERa
expression in metastases (termed receptor conversion;
6–25% of cases) (Hoefnagel et al., 2010; Van Poznak
et al., 2015). Cumulatively, the currently known (ge-
nomic) aberrations only explain about 40–60% of
endocrine-resistant cases in the metastatic setting, and
other mechanisms of acquired resistance to hormonal
therapies are likely to exist. FOXA1 and GATA3,
both well recognized as luminal breast cancer-defining
genes (Perou et al., 2000), play crucial roles in genomic
functions of ERa. FOXA1 is required for ERa–chro-
matin interactions by rendering the chromatin accessi-
ble at designated ERa binding sites, in both hormone-
responsive and tamoxifen-resistant cells (Hurtado
et al., 2011). GATA3 facilitates FOXA1–chromatin
interactions and directly affects chromatin loops that
involve ERa (Theodorou et al., 2013). Jointly, FOXA1
and GATA3 are essential and sufficient to enable
ERa–chromatin interactions, responsive gene activa-
tion, and cell proliferation (Kong et al., 2011).
FOXA1 expression was found increased in metastases
in relation to primary breast cancer (Ross-Innes et al.,
2012). However, it remains to be determined whether
levels of FOXA1 and GATA3 in metastatic breast can-
cer are affected by adjuvant endocrine therapy. We
therefore immunohistochemically stained ERa,
FOXA1, and GATA3 in metastatic breast cancer speci-
mens from various sites. To find an explanation for the
large variation in FOXA1 and GATA3 levels in samples
of pleural metastases, we combined immunohistochem-
istry (IHC) data with prior treatment history in the
adjuvant setting. We also combined these data with
endocrine treatment response in the palliative setting.
Even though GATA3 levels were not affected in the
metastases after adjuvant endocrine therapy, FOXA1
levels were selectively decreased in pleural metastases
that arose after adjuvant treatment with endocrine
therapeutics. Furthermore, patients with decreased
FOXA1 levels were less responsive to endocrine thera-
peutics in the metastatic setting. These results suggest
metastatic site-selective variations of two well-known
ERa pioneer factors: GATA3 and FOXA1. Decreased
FOXA1 levels in ERa-positive pleural metastases are
exclusively observed after prior adjuvant endocrine
exposure, linking diminished FOXA1 levels with hor-
mone irresponsiveness and endocrine therapy resis-
tance in this setting.
2. Materials and methods
2.1. Patient material
A total of 210 individual ER-positive, distant metas-
tases of female patients with breast cancer were col-
lected prospectively (pleural effusions only; n = 21)
and retrospectively (both solid metastases and pleural
effusion specimens; n = 189; Table 1). When available,
paired formalin-fixed paraffin-embedded (FFPE) mate-
rial of the primary breast tumor was collected as well
(n = 81). The retrospectively obtained specimens
(FFPEs) were collected in hospitals across The Nether-
lands: the Groene Hart Hospital Gouda, the Onze
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Lieve Vrouwe Gasthuis (Amsterdam), the Orbis Medi-
cal Center (Sittard), the Medical Center Leeuwarden,
the University Medical Center St. Radboud (Nijme-
gen), the Meander Medical Center (Amersfoort), the
Atrium Medical Center (Heerlen), the VieCuri Medical
Center (Venlo), the Leiden University Medical Center,
Bronovo Hospital (The Hague), Canisius Wilhelmina
Hospital, Rijnstate Hospital (Arnhem), Diakonessen-
huis (Utrecht), Isala Clinics (Zwolle), St. Franciscus
Gasthuis (Rotterdam), Amphia Hospital (Breda), the
Netherlands Cancer Institute (Amsterdam), and the
University Medical Center Utrecht (described in Hoef-
nagel et al., 2010, 2012). Original diagnoses were made
between 1988 and 2013.
2.2. Prospective pleural tumor cell collection and
isolation
Fluid isolated from the pleural cavity was collected
directly after drainage from patients at the University
Medical Center Utrecht and the Netherlands Cancer
Institute in Amsterdam. The cells in the pleural effu-
sions were isolated by centrifugation, the erythrocytes
were lysed (erythrocyte lysis buffer [pH 7.4]: 75 mM
NH4Cl, 5 mM KHCO3, 400 lL 500 mM EDTA, and
500 mL ddH2O), and the remaining cells were either
formalin-fixed and paraffin-embedded (Cellient; Holo-
gic, 40180I10D0), or cryo-stored at 80 °C (DMSO).
Original diagnoses were made between 2014 and 2017.
2.3. Tissue processing
Immunohistochemical staining was performed on both
pleural effusion samples and tissue microarrays (TMAs)
(Jiwa et al., 2014) from 97 primary tumors and paired
solid metastases. Three core biopsies (0.6 mm in diame-
ter) of histologically representative regions of each
tumor were used to construct the TMAs. For each
FFPE sample, hematoxylin–eosin-stained slides of the
paraffin blocks were reviewed by an experienced breast
pathologist (PJvD) to confirm the presence of malig-
nancy. For the pleural effusions, only samples contain-
ing at least 20 tumor cells were selected. Ber-EP4
monoclonal antibody staining (Epcam, 1 : 40, CCI24,
DAKO) that labels epithelial tissues, but does not react
with mesothelial cells, was used to confirm presence and
quantity of tumor cells in the effusions. Due to loss of
cores or not enough tumor cells left in the cores, 81/97
cases could be used for the final analyses.
This study was performed in accordance with the
institutional medical ethical guidelines. The use of
anonymous or coded leftover material for scientific
purposes is part of the standard treatment agreement
with patients, and therefore, informed consent was not
required according to Dutch law (van Diest, 2002) for
patients not actively opting out.
2.4. Immunohistochemical analyses
Sections of 4 lm were cut from the FFPE blocks of
the pleural effusions, their primary breast tumors (if
available), and the TMAs. IHC was performed with
the Ventana autostainer (Roche, Tucson, Arizona,
USA) according to the manufacturer’s instructions.
Mouse monoclonal antibodies used were against ERa
Table 1. Clinicopathological characteristics of paired primary
tumors and distant metastases
Feature Grouping
N or
value %
Age at diagnosis of primary
tumor (n = 81)
Mean 52
Range 27–83
Tumor size in cm (n = 81) Mean 3.1
Range 0.2–15
Unknown 22
Histological grade I 4 5
II 26 32
III 31 38
Unknown 20 25
PR-status primary
tumor (n = 81)
Positive 71 88
Negative 10 12
Unknown 0 0
HER2-status primary
tumor (n = 81)
Positive 19 23
Negative 62 77
Unknown 0 0
Lymph node status (n = 81) Positive 31 38
Negative 18 22
Unknown 32 40
Time between primary tumor and metastasis in days
Total (n = 81) Mean 373
Range 0–2839
Solid metastases (n = 58) Mean 152
Range 28–459
Pleural effusions (n = 23) Mean 446
Range 0–2839
Location of metastasis
(n = 210)
Liver 2 1
Lung 7 3
Brain 18 9
Skin 23 11
Bone 4 2
Uterus/ovary 4 2
Pleural effusion 152 72
Adjuvant therapy (n = 210)
Endocrine therapy Yes 72 34
No 63 30
Unknown 75 36
Chemotherapy Yes 69 33
No 53 25
Unknown 88 42
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(RTU, SP1; Roche, Tucson, USA), FOXA1
(1 : 100 000, WMAB-2F83, Seven Hills Bioreagents),
GATA3 (1 : 300, 5852 Cell Signaling Technology,
Bioke), and Ber-EP4 (Epcam, 1:40, CCI24, DAKO).
Appropriate controls were used throughout.
Scoring of IHC slides was performed by two obser-
vers (PJvD and WAMES), who were blinded to clini-
copathologic and molecular data. The percentage of
positively stained nuclei was estimated side by side
with the Ber-EP4-stained slide as a reference. For the
TMAs, the mean score of all three cores was used as
the final score per tumor.
2.5. Statistical analyses
IHC for ERa, FOXA1, and GATA3 positivity was
assessed with a 1% threshold for positivity (ASCO
guidelines) (Hammond et al., 2010), regardless of
staining intensity. Percentages of nuclei expressing
ERa, FOXA1, and GATA3 in primary tumors and
their metastases in pleural effusions and solid tissues
were compared by Wilcoxon signed rank test. Differ-
ences between hormonal treatment regimens were
determined by Mann–Whitney U-test and correlations
between FOXA1 and GATA3 loss with Spearman’s
rho. Dichotomization for FOXA1 and GATA3 expres-
sion in treated and untreated patients was performed
with ROC curves and compared with Fisher’s exact
test. Progression during treatment after first pleural
effusion was visualized using Kaplan–Meier survival
plots. Univariate and multivariate Cox proportional
hazard regression analyses were performed to calculate
hazard ratios (HR). All statistical analyses were per-
formed using IBM SPSS Statistics version 21 and
GraphPad Prism 6 (GraphPad Software, USA).
3. Results
3.1. Correlations of ERa, FOXA1, and GATA3 in
primary and metastatic breast cancers
We gained access to 210 ERa-positive (> 1% nuclear
staining) metastatic breast cancer samples, with an
enrichment for pleural effusion metastases (n = 152). In
addition, two liver, seven lung, eighteen brain, twenty-
three skin, four bone, and four uterus or ovary metas-
tases were included. For 39% (81/210) of these samples,
paired primary breast cancers could be retrieved from
the pathology registry (for clinicopathological variables,
Table 1). As expected for transcription factors, clear
nuclear signal intensity was observed for ERa, FOXA1,
and GATA3 in the primary breast cancers as well as the
metastatic samples (Fig. 1A). Out of 135 patients for
whom treatment history was present, 72 patients
received adjuvant endocrine therapy (53%). As expected
and in line with literature (Perou et al., 2000), most
ERa-positive primary breast cancers we studied also
expressed FOXA1 (n = 73/81, 90%; staining percentage
range 3–100%, mean 70%) and GATA3 (n = 63/81,
78%; staining percentage 1–100%, mean 58%). Signifi-
cant correlations were found between levels of ERa and
FOXA1 (q = 0.268; P = 0.018; Spearman’s rho), ERa
and GATA3 (q = 0.549; P < 0.001; Spearman’s rho),
and GATA3 and FOXA1 (q = 0.707; P < 0.001; Spear-
man’s rho) in the primary breast tumors and in the
metastatic setting (q = 0.349, P < 0.001; q = 0.459,
P < 0.001; q = 0.535, P < 0.001, respectively; Spear-
man’s rho). Qualitatively, we observed a bimodal distri-
bution in the primary samples for ERa, FOXA1, and
GATA3, separating high- and low-percentage samples
in two distinct groups (Fig. 1B; statistics are shown in
Fig. 1C). These patterns differed between the different
metastatic sites, with FOXA1 highly expressed in practi-
cally all skin and brain metastases, while GATA3 more
often showed lower expression levels in brain metas-
tases. For pleural effusion samples, a different pattern
was found for all factors, displaying a large variation in
signal intensity of ERa, FOXA1, and GATA3 between
samples, occupying the full dynamic range between 0
and 100% (Fig. 1B; statistics are shown in Fig. 1C).
Compared to levels of GATA3 and FOXA1 in pri-
mary tumors, average levels were similar in some meta-
static sites, while expression differed in others (Fig. 1C).
Jointly analyzing all metastases as one population, this
trend was not significant for FOXA1 (P = 0.730; mean
staining percentage primary 71% vs. metastasis 64%;
Wilcoxon signed rank test), while for GATA3 it was
(P = 0.036; mean staining percentage primary 59% vs.
metastasis 38%; Wilcoxon signed rank test). In contrast
to pleural effusions but in agreement with previous
reports (Ross-Innes et al., 2012; Tangen et al., 2014),
FOXA1 levels were increased in solid metastases
(P = 0.002; mean staining percentage primary 53% vs.
metastasis 74%; Wilcoxon signed rank test; Fig. S3).
This effect was most prominent in solid metastases to
the skin (P = 0.070; Wilcoxon signed rank test;
Fig. 1C). No difference in GATA3 level was found
between primary breast cancer and solid metastases
(P = 0.658; mean staining percentage primary 40% vs.
metastasis 42%; Wilcoxon signed rank test; Fig. S3).
3.2. FOXA1 and GATA3 expression in relation to
adjuvant endocrine therapy exposure
Even though FOXA1 and GATA3 levels have previ-
ously been studied in the context of primary and
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Fig. 1. Loss of FOXA1 and GATA3 expression in ERa-positive metastatic breast cancer. (A) Immunohistochemical analyses of ERa, FOXA1,
and GATA3 in primary breast tumors and matched metastatic breast tumor cells. (B) Scatterplot visualizing immunohistochemical staining
percentage of ERa vs. FOXA1, ERa vs. GATA3, and FOXA1 vs. GATA3 in primary breast cancer (orange) and skin (purple), brain (blue), and
pleural effusion metastases (green). (C) Quantification of IHC staining for ERa, FOXA1, and GATA3 in primary breast cancers and
metastases to the skin, brain, and pleural cavity using Wilcoxon signed rank test. Error bars indicate 95% confidence interval.
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metastatic breast cancer, no thorough assessment has
been performed to date in relation to prior endocrine
therapy usage.
We chose to focus on pleural effusion metastases
(n = 152), due to the large interpatient variation
observed in levels of FOXA1 and GATA3 for this
metastatic site. As ESR1 activating hotspot muta-
tions are reported enriched in endocrine-resistant
metastatic breast tumors (Toy et al., 2013), we tested
for any of the helix 12 activating hotspot mutations
in 11 randomly selected samples from adjuvant
tamoxifen-treated patients (Fig. S1). None of these
samples exposed activating hotspot mutations. There-
fore, it seems unlikely that activating ESR1 point
mutations is a major contributor in our cohort of
pleural metastases.
Changes in FOXA1 levels between primary tissue
and paired pleural metastases typically co-occurred
with changes in GATA3 in the same samples
(q = 0.546, P = 0.007; Spearman’s rho; Fig. 2A). The
same trend was encountered for primary tumors
compared to pleural effusion and solid metastases
(q = 0.458, P = 0.001; Spearman’s rho; Fig. S4).
Patients that had received adjuvant endocrine ther-
apy showed a trend toward a greater decrease (D%)
of FOXA1 expression levels in pleural metastases
compared to the primary tumor vs. patients that
had not received adjuvant therapy (P = 0.085;
Mann–Whitney U-test; Fig. 2B), while this was not
the case for GATA3 (P = 0.779; Mann–Whitney U-
test). Also in unpaired analyses, FOXA1 expression
in pleural effusions was significantly lower in
patients who received adjuvant endocrine therapy
compared to the pleural samples of patients who did
not receive any adjuvant endocrine treatment
(P = 0.021; n = 100; Mann–Whitney U-test; Fig. 2C).
This effect was not seen for GATA3 (P = 0.46;
n = 100; Mann–Whitney U-test) or ERa (P = 0.60;
n = 100; Mann–Whitney U-test). Tamoxifen was the
most dominant adjuvant endocrine treatment in this
cohort (adjuvant tamoxifen n = 42, adjuvant aro-
matase inhibitor n = 4, combination of both n = 8),
preventing sufficiently powered subanalysis based on
type of endocrine therapy.
FOXA1 and GATA3 levels in solid metastases
were not associated with adjuvant hormonal therapy,
in both unpaired (P = 0.197 for FOXA1 and
P = 0.568 for GATA3; Mann–Whitney U-test) and
paired analyses (untreated patients: P = 0.073 for
FOXA1 and P = 0.638 for GATA3; patients receiv-
ing adjuvant hormonal therapy: P = 0.088 for
FOXA1 P = 0.296 for GATA3; Wilcoxon signed
rank test; Fig. S2).
3.3. FOXA1 and GATA3 expression levels in
relation to treatment response in the metastatic
setting
As FOXA1 and GATA3 are described as essential fac-
tors in ERa functioning (Hurtado et al., 2011; Theo-
dorou et al., 2013), decreased levels of either of these
two factors would be associated with nonfunctional
ERa and would imply resistance to endocrine thera-
peutics in this setting. This was tested in all pleural
metastatic samples of patients receiving endocrine
treatment for metastatic disease, in which time on first
endocrine therapy after pleural effusion before switch-
ing to another type of treatment (mostly due to disease
progression) was used as endpoint. FOXA1 decrease
was significantly associated with a shorter time on first
endocrine therapy (Fig. 3A; P = 0.042; HR = 0.463;
95% CI: 0.220–0.973; log-rank test; cutoff for positiv-
ity determined with ROC curves). For GATA3, this
effect was not observed (Fig. 3B; P = 0.937;
HR = 0.976; 95% CI: 0.536–1.776; log-rank test). To
adjust for possible confounders, univariate Cox pro-
portional hazard regression analysis was performed on
traditional predictive clinicopathological factors: dis-
ease-free interval, age at diagnosis of primary tumor,
tumor size, immunohistochemical markers (PR and
HER2), and histological grade and type (Table S1).
Only disease-free interval and histological type showed
significant association with time to treatment switch
(Table 2). When put in a multivariate model, a shorter
disease-free interval was correlated with a longer time
to treatment switch (HR: 2.653, 95% CI: 1.074–6.552,
P = 0.034), independent of FOXA1 and GATA3
decrease.
Cumulatively, these data illustrate that FOXA1
expression is decreased in progressive metastatic breast
cancer to the pleural cavity. This decrease in FOXA1
levels in metastases is discordant with previous reports
in solid metastases (Ross-Innes et al., 2012), suggesting
organotropism of FOXA1 levels in metastatic breast
cancer. Furthermore, FOXA1 levels were decreased
exclusively for the patients who received endocrine
therapy in the adjuvant setting, and were indicative for
resistance to endocrine intervention in metastatic
disease.
4. Discussion
Years of continuous drug exposure in the adjuvant set-
ting provides a massive selection pressure on the
tumor cells for evading the blocking effects of endo-
crine treatment (Robinson et al., 2013; Toy et al.,
2013). Recently, several reports identified a distinct set
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of activating point mutations within the ERa trans-
activating domain, only found in ~ 20–40% of metas-
tases with acquired endocrine therapy resistance (Jesel-
sohn et al., 2017; Robinson et al., 2013; Toy et al.,
2013). Also, epigenetic reprogramming of the chro-
matin landscape can underlie endocrine therapy-
resistant breast cancer by switching from ERa to
NOTCH signaling (Magnani et al., 2013). In another
6–25% of patients, ERa expression is lost in metas-
tases while the primary tumor was ERa-positive (Van
Poznak et al., 2015). Still, these known mechanisms of
endocrine therapy resistance recapitulate only about
Fig. 2. Decreased FOXA1 expression levels in metastases after prior tamoxifen exposure. (A) Scatterplot visualizing percentage change of
FOXA1/GATA3 levels in paired pleural metastases vs. primary breast tumors from the same patients. Correlation was calculated with
Spearman’s rho. Samples from patients receiving adjuvant tamoxifen (green), no adjuvant endocrine treatment (red), or unknown adjuvant
treatment (blue) are visualized separately. (B) Waterfall plot showing changed expression of ERa (left), FOXA1 (middle), and GATA3 (right) in
paired analyses on pleural metastases relative to primary breast cancers, compared with Mann–Whitney U-test. Patients receiving adjuvant
tamoxifen (green), no adjuvant endocrine treatment (red), or unknown adjuvant treatment (blue) are indicated. (C) Expression levels of ERa
(left), FOXA1 (middle), and GATA3 (right) in pleural metastases, from patients who either did (green) or did not (red) receive adjuvant
endocrine treatment, compared with Mann–Whitney U-test. Mean is indicated.
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40–60% of all observed resistance, leaving many endo-
crine therapy unresponsive cases unexplained. In the
current study, we position decreased levels of FOXA1
as a potential novel mechanism of acquired endocrine
therapy resistance, which could be further developed
as a biomarker.
GATA3 and FOXA1 are both essential transcrip-
tion factors for ERa action, enabling its chromatin
interactions and consequently facilitating ERa-respon-
sive gene activity. As such, both GATA3 and FOXA1
are termed key luminal breast cancer-defining genes
and are expressed in virtually all ERa-positive primary
breast cancers (Perou et al., 2000). In pleural effusion
metastases, however, FOXA1 expression is decreased
under evolutionary selection pressure of continuous
ERa blockade, while GATA3 levels were not affected.
Persistent and increased FOXA1 expression was
seen in solid metastases that arose from an ERa-posi-
tive breast cancer, regardless of the sites of metastasis
(Ross-Innes et al., 2012). This is consistent with our
data, where we find FOXA1 generally increased rela-
tive to the primary tumor in metastases to the skin
and brain. However, in pleural metastases no increase
in FOXA1 levels was observed relative to the primary
tumor, implicating metastatic site organotropism in
relation to FOXA1 levels. In line with this concept, we
did not observe any of the previously identified hot-
spot ESR1 mutations, found in 20–40% of metastatic
breast cancers that progressed after adjuvant endocrine
therapy (Robinson et al., 2013; Toy et al., 2013). Pos-
sibly, malignant pleural effusions are less enriched for
Fig. 3. FOXA1 expression levels are associated with response to
endocrine therapy in the metastatic setting. Kaplan–Meier plot
indicating time to treatment switch after first pleural effusion,
separately analyzing FOXA1 (top) and GATA3 (bottom), calculated
with log-rank test. Dichotomization for FOXA1 and GATA3
expression in treated and untreated patients was performed with
ROC curves.
Table 2. Univariate Cox proportional hazard regression analysis of
time to treatment switch after first pleural effusion (n = 61)
Category N HR 95% CI P
Disease-free interval
<5 years 13 2.541 1.074–6.012 0.034
> 5 years 16 1
Unknown 32
Age at diagnosis
<55 years 18 1
≥ 55 years 16 1.238 0.592–2.590 0.571
Unknown 27
Type
Ductal 31 1
Lobular 4 0.284 0.090–0.899 0.032
Unknown 26
Stage
I/II 18 1
III 6 0.532 0.176–1.607 0.263
Unknown 37
Size
≤ 2 cm 13 0.587 0.275–1.254 0.169
> 2 cm 17 1
Unknown 31
PR (IHC) primary tumor
<1% 7 0.760 0.305–1.895 0.557
≥ 1% 18 1
Unknown 36
HER2 (IHC) primary tumor
0/1 + /2 + 23 1
3 + 2 0.699 0.156–3.138 0.640
Unknown 36
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ESR1 mutations as compared to solid metastases.
However, our cohort is enriched for cases who
received tamoxifen in the adjuvant setting, and activat-
ing ESR1 mutations are mostly identified in patients
who previously received aromatase inhibitors and
rarely observed in patients solely receiving tamoxifen
(Reinert et al., 2017), indicating that our study is pos-
sibly underpowered for stronger conclusions.
In about 20% of malignant pleural effusions that
arose after adjuvant endocrine therapy, ERa expres-
sion is lost (Van Poznak et al., 2015), and endocrine
therapy will not be effective. We hypothesize that
decreased FOXA1 levels in metastases that developed
under selection pressure of continued endocrine thera-
peutics, results in a comparable disruption of the ERa
signaling axis and loss of sensitivity to endocrine ther-
apies. Reports that describe increased FOXA1 levels in
solid metastases limited the analyses in relation to the
primary tumor, without incorporating treatment infor-
mation (Ross-Innes et al., 2012). We now show that
adjuvant endocrine therapy associates with decreased
FOXA1 levels in pleural metastases.
Several guidelines advise to reassess ERa status in
metastases by immunohistochemistry (Carlson et al.,
2012; Hammond et al., 2010). This may identify poten-
tial loss of ERa expression, but does not provide any
information on ERa functionality in case ERa expres-
sion is maintained. As ERa expression alone is not per
definition informative about its functional activity,
additional biomarkers may aid in identifying ERa
functionality. We show here that decreased FOXA1
expression is associated with poor outcome after endo-
crine therapy for pleural metastases, even though these
results do require confirmation in a second cohort.
Most importantly, validation of these findings in an
independent case–control study or randomized trial of
endocrine therapy vs. nil (or another anticancer ther-
apy not targeting the ER) would be required to assess
whether FOXA1 levels are a prognostic factor or
whether they are predictive for endocrine therapy
response in the metastatic setting.
This study design enabled us to study differences in
immunohistochemical markers between primary
tumors and metastases by paired analyses. To our
knowledge, this is the largest sample set in which influ-
ence of endocrine therapy is investigated on FOXA1
and GATA3 expression in paired primary tumors and
metastases. However, the influence of tumor hetero-
geneity should not be overlooked. As we used patient
samples that also were used for diagnostic purposes,
only parts of the tumors were available for our analy-
ses. Also, treatment history was not present for all
patients. Furthermore, we used immunohistochemical
staining percentages to compare ERa, FOXA1, and
GATA3 in primary tumors vs. metastases, and as this
is a semiquantitative approach, it would be very valu-
able to better quantify these findings with other molec-
ular techniques in further validation studies. We
deliberately chose to limit data analyses and interpre-
tation on the most robust variable in this setting, being
percentage of positive nuclei, as reproducibility for
scoring intensity of FOXA1 and GATA3 immunohis-
tochemistry appeared to be lower compared to per-
centage of positive nuclei. Further, FOXA1 intensity
turned out to be affected by fixation time, while per-
centage of staining was not. Finally, this data set was
largely enriched for pleural effusion metastases, pre-
venting us to draw strong conclusions on solid metas-
tases. Recently, we already showed that steroid
hormone receptor expression can differ largely between
primary tumors and solid and effusion metastases in
the same patient (Schrijver et al., 2017). Furthermore,
as it is currently unknown to what degree the hor-
monal levels are comparable between different solid
metastases and pleural effusions, different evolutionary
selection pressure may occur between these different
metastatic sites.
As around 11% of patients with breast cancer even-
tually present with symptomatic pleural effusions and
at autopsy 36–65% of patients retrospectively suffered
from this condition (American Thoracic Society, 2000;
Apffelstaedt et al., 1995), future studies should vali-
date our findings in other cohorts and may reveal pre-
dictive biomarkers for endocrine therapy sensitivity in
pleural metastases, facilitating tailored treatment selec-
tion for this large group of patients with metastatic
disease.
5. Conclusions
Immunohistochemical ERa, GATA3, and FOXA1
expression levels vary between primary breast tumors
and paired metastases. FOXA1 is reduced in pleural
metastases of patients who received endocrine thera-
pies in the adjuvant setting. Decreased FOXA1 levels
are associated with poor outcome after endocrine ther-
apy in the metastatic setting.
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